A Study to Evaluate the Efficacy and Safety of Obinutuzumab in Participants With Systemic Lupus Erythematosus

To join this study, you would need to be an adult between 18 and 75 years old diagnosed with Systemic Lupus Erythematosus (lupus) for at least 12 weeks. Your lupus also needs to be active, meaning it's currently causing noticeable symptoms that your doctor can measure. You would also need to be already taking at least one of the standard medicines for lupus, such as steroids, antimalarials, or other immunosuppressants, at a stable dose.

There are also some reasons why you might not be able to join. For example, if you are pregnant or breastfeeding, you wouldn't be able to participate. Also, if your lupus has severely affected your kidneys, or if you have a serious ongoing infection, this study might not be suitable. Certain other treatments you might have received recently could also prevent you from joining. The study team will check these details carefully.

Taking part in this study would involve regular visits to the clinic so the study team can monitor your health and how you respond to the treatment. You would receive either the new study medication, Obinutuzumab, or a placebo (dummy treatment) through an infusion, which means it would be given through a drip into your arm. You might also receive other common medications like paracetamol or specific anti-allergy medicines before your infusions to help prevent any reactions.

Throughout the study, you would have various assessments, including blood tests, physical examinations, and questionnaires to track your lupus symptoms and overall well-being. The total duration of your participation would involve the treatment period and a follow-up period to ensure your safety and track long-term effects. The study doctors and nurses will explain the full schedule and how often you'd need to attend.